Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 21, 2015; 21(15): 4635-4643
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4635
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4635
Table 1 Baseline and tumor characteristics of the study patients
Liver resection group | TACE group | P value | |
218 | 281 | ||
Age (yr) | 52.1 ± 12.5 | 52.0 ± 13.5 | 0.950 |
Sex (M/F) | 162/56 | 210/71 | 0.915 |
Weight (kg) | 67.6 ± 9.5 | 66.8 ± 9.4 | 0.358 |
Height (cm) | 165.5 ± 8.7 | 164.9 ± 9.0 | 0.496 |
BMI (kg/m2) | 23.6 ± 2.5 | 23.6 ± 2.4 | 0.870 |
Cirrhosis etiology (HBV/HCV/negative/other) | 193/5/9/11 | 256/6/6/13 | 0.352 |
MELD score | 5.4 ± 1.8 | 5.5 ± 1.7 | 0.607 |
Child score (A/B/C) | 162/56/0 | 222/59/0 | 0.218 |
EOCG score (0/1/2) | 161/29/28 | 211/39/31 | 0.697 |
PHT (yes/no) | 182/36 | 244/37 | 0.668 |
Tumor diameter of the largest target (cm) | 6.2 ± 2.3 | 7.6 ± 2.2 | < 0.001 |
AFP level (ng/mL) | 2388.5 ± 7916.0 | 2650.1 ± 8514.4 | 0.726 |
0-400 ng/mL | 120 | 136 | |
400-800 ng/mL | 11 | 26 | |
800-1200 ng/mL | 15 | 13 | |
≥ 1210 ng/mL | 72 | 106 | |
NLR ≥ 4 (yes/no) | 109/109 | 160/121 | 0.123 |
Obvious arterial phase enhancement (yes/no) | 175/43 | 222/59 | 0.727 |
Diagnostic method (enhanced CT/MRI/biopsy) | 172/36/10 | 238/27/16 | 0.127 |
Table 2 Post-operative complications in the two patient groups n (%)
Resection group | TACE group | P value | |
218 | 281 | ||
Complications (Clavien-Dindo classification) | 68 (31.2) | 154 (54.8) | < 0.001 |
Grade I (without drugs, conservative treatment) | 18 (8.3) | 77 (27.4) | |
Grade II (simple medicine treatment) | 12 (5.5) | 56 (19.9) | |
Grade IIIa (therapeutic operation under local anesthesia) | 7 (3.2) | 5 (1.8) | |
Grade IIIb (operational treatment under general anesthesia) | 5 (2.3) | 2 (0.7) | |
Grade IVa (single organ function failure) | 5 (2.3) | 1 (0.4) | |
Grade IVb (multiple organ failure) | 4 (1.8) | 1 (0.4) | |
Grade V (In-hospital death) | 4 (1.8) | 2 (0.7) | 0.254 |
Minor complications (I-II) | 30 (13.8) | 133 (43.3) | < 0.001 |
Major complications (III-V) | 38 (17.4) | 11 (3.9) | < 0.001 |
30-d mortality | 5 (2.3) | 3 (1.1) | 0.280 |
90-d mortality | 8 (3.7) | 7 (2.5) | 0.445 |
Table 3 Univariate analyses show factors of overall survival
Variables | n | Overall survival rate |
499 | P value | |
Age < 60 (yes/no) | 341/158 | 0.041 |
Gender (M/F) | 372/127 | 0.596 |
BMI ≥ 26 (yes/no) | 72/427 | 0.268 |
Cause of liver diseases (HBV/HCV/no/others) | 449/11/15/24 | 0.779 |
Child-Pugh Score (A/B) | 384/115 | 0.897 |
ECOG score (0/1/2) | 372/68/59 | 0.594 |
PHT (yes/no) | 425/74 | < 0.001 |
ALB ≥ 35 g/L (yes/no) | 275/224 | 0.221 |
Platelets ≥ 100 × 109/L (yes/no) | 177/322 | 0.923 |
HB ≥ 120 g/L (yes/no) | 331/168 | 0.602 |
Creatinine ≥ 100 μmol/L (yes/no) | 49/450 | 0.675 |
NLR ≥ 4 (yes/no) | 269/230 | < 0.001 |
AFP level (1-400/400-800/800-1200/ > 1200 ng/mL) | 256/37/28/178 | 0.218 |
Tumor diameter > 6 cm (yes/no) | 306/193 | < 0.001 |
Obvious arterial phase enhancement (yes/no) | 397/102 | 0.361 |
Diagnostic method (enhanced CT/MRI/biopsy) | 410/63/26 | 0.587 |
Therapy (liver resection/TACE) | 218/281 | 0.437 |
Table 4 Multivariate analyses of factors that contributed to the overall survival rates
Variables | HR | 95%CI | P value |
Age < 60 | 1.129 | 0.981-1.282 | 0.121 |
PHT | 1.228 | 0.908-1.556 | 0.262 |
NLR ≥ 4 | 1.431 | 0.992-1.781 | 0.128 |
Tumor diameter > 6 cm | 1.328 | 1.002-1.783 | 0.048 |
- Citation: Zhang DZ, Wei XD, Wang XP. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma. World J Gastroenterol 2015; 21(15): 4635-4643
- URL: https://www.wjgnet.com/1007-9327/full/v21/i15/4635.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i15.4635